Respiratory

2018/10/17MEDICAL UPDATE

WCLC 2018: Variety of approaches can work in oligometastatic disease

By Thomas R Collins / Interviewer Esther Drain Creative approaches that can be used to keep control of oligometastic disease in patients with non-small cell lung cancer were discussed here at the IASLC 19th World Conference on Lung Cancer.

READ MORE

2018/10/17MEDICAL UPDATE

WCLC 2018: Lung cancer stigma is detrimental to patient care

Interviewer Esther Drain Dr Jesme Fox (Roy Castle Lung Cancer Foundation, UK) discusses research she presented showing that lung cancer stigma is detrimental to patients' care.

READ MORE

2018/10/17MEDICAL UPDATE

WCLC 2018: Importance of QOL outcome measures in clinical trials

Interviewer Esther Drain WCLC co-Presidents Professor Andrea Bezjak and Dr Natasha Leighl (both of Toronto, Canada) discuss research from their centre on the iimportance of QOL outcome measures in clinical trials.

READ MORE

2018/10/17MEDICAL UPDATE

WCLC 2018: Accessibility & quality of life: a patient focus at WCLC

By Thomas R Collins / Interview by Esther Drain Talk of progress in cancer treatment can ring hollow if the new, life-lengthening therapies are not widely available, the president-elect of the European Society of Medical Oncology said here at the IASLC 19th World Conference on Lung Cancer.

READ MORE

2018/10/17MEDICAL UPDATE

WCLC 2018: PACIFIC: durvalumab results impressive, but not without questions

By Thomas R Collins / Interview by Esther Drain Patients with unresectable stage III non-small cell lung cancer taking durvalumab had significantly better overall survival than those on placebo after standard chemotherapy and radiation, according to the latest results of the phase III PACIFIC trial presented here at the IASLC 19th World Conference on Lung Cancer.

READ MORE

2018/10/17MEDICAL UPDATE

WCLC 2018: Early ALTA-1L data encouraging for brigatinib

By Thomas R Collins / Interviews by Esther Drain The ALK- and ROS1-inhibitor brigatinib showed a better progression-free survival (PFS) compared to the ALK-inhibitor crizotinib in the first interim analysis of a head-to-head trial in patients with ALK-positive non-small cell lung cancer (NSCLC) who hadn’t yet received an ALK-inhibitor, researchers said here in the Plenary at the IASLC 19th World Congress on Lung Cancer.

READ MORE

2018/10/17MEDICAL UPDATE

WCLC 2018: Success of combined screening and smoking cessation pilots

Interviews by Esther Drain Professor Gail Darling (WCLC co-President, Toronto, Canada) discusses the success of combined screening and smoking cessation pilot in Ontario.

READ MORE

2018/10/17MEDICAL UPDATE

WCLC 2018: Do we have a UK-wide screening programme that is ready to implement?

Interviewer: Esther Drain Dr Jesme Fox (Roy Castle Lung Cancer Foundation, UK) and Professor David Baldwin (Nottingham, UK) detail current UK pilots and a screening protocol that is currently going through the NHS England gateway process.

READ MORE

2018/10/17MEDICAL UPDATE

WCLC 2018: NELSON – CT screening saves lives

By Thomas R Collins / Interviewer Esther Drain A randomised, controlled screening trial for lung cancer involving almost 16,000 people in the Netherlands and Belgium found that CT screening produced a 26% reduction in lung cancer deaths among at-risk men over 10 years, according to data presented here at the IASLC 19th World Conference on Lung Cancer.

READ MORE

2018/10/17MEDICAL UPDATE

WCLC 2018: Highlights

Interviewer: Esther Drain The IASLC 19th World Conference on Lung Cancer (WCLC) was full of highlights, including 3 plenary abstracts being presented in the New England Journal of Medicine and involvement from patients and patient advocates. Watch the  montage of comments from delegates to get an idea of the excitement generated here in Toronto.

READ MORE